In vitro selection of variants resistant to β-lactams plus β-lactamase inhibitors in CTX-M β-lactamases: Predicting the in vivo scenario?

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4530-4536

  Ripoll, Aida ^a   Baquero, Fernando ^a,b   Novais, Ǎngela ^a,c   Rodríguez Domínguez, Mario J ^a   Turrientes, Maria Carmen ^a   Cantón, Rafael ^a,b   Galán, Juan Carlos ^a,b  

^a INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^b CSIC   (Spain)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE CLUSTER; GENE MUTATION; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MUTAGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLEIOTROPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY;

AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; CLAVULANIC ACID; DNA, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; EVOLUTION, MOLECULAR; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PENICILLANIC ACID; PIPERACILLIN; PLASMIDS; SELECTION, GENETIC;

EID: 80052824532     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00178-11     Document Type: Article

References (61)

1. Aumeran, C., et al. 2003. Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum β-lactamase CTX-M-9. Antimicrob. Agents Chemother. 47:2958-2961.
2. Bae, I. K., et al. 2007. Genetic and biochemical characterization of GES-5, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 58:465-468. (Pubitemid 47208536)
3. Bermudes, H., et al. 1999. Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived β-lactamase in a clinical isolate of Klebsiella oxytoca. Antimicrob. Agents Chemother. 43:1657-1661. (Pubitemid 29331243)
4. Bonnet, R., et al. 2001. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly. Antimicrob. Agents Chemother. 45:2269-2275.
5. Bush, K., and G. A. Jacoby. 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54:969-976.
6. Cantón, R., M. I. Morosini, O. M. de la Maza, and E. G. de la Pedrosa. 2008. IRT and CMT beta-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 14(Suppl. 1):53-62.
7. Castanheira, M., H. S. Sader, and R. N. Jones. 2010. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb. Drug Resist. 16:61-65.
8. Centers for Disease Control and Prevention. 2010. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States, 2010. MMWR Morb. Mortal. Wkly. Rep. 59:750.
9. Coque, T. M., F. Baquero, and R. Cantón. 2008. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 13:pii:19044.
10. Coque, T. M., et al. 2008. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg. Infect. Dis. 14:195-200.
11. KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. J. Antimicrob. Chemother. 65:1608-1614.
12. Díaz, M. A., et al. 2010. Diversity of Escherichia coli strains producing extended-spectrum β-lactamases in Spain: second nationwide study. J. Clin. Microbiol. 48:2840-2845.
13. Dubois, V., et al. 2008. Molecular and biochemical characterization of SHV- 56, a novel inhibitor-resistant β-lactamase from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 52:3792-3794.
14. Dumartin, C., et al. 2010. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J. Antimicrob. Chemother. 65:2028-2036.
15. Falagas, M. E., A. C. Kastoris, A. M. Kapaskelis, and D. E. Karageorgopoulos. 2010. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect. Dis. 10:43-50.
16. Galán, J. C., M. I. Morosini, M. R. Baquero, M. Reig, and F. Baquero. 2003. Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic delta-ampC Escherichia coli conferring resistance to cefotaxime and β-lactamase inhibitors and increased susceptibility to cefaclor. Antimicrob. Agents Chemother. 47:2551-2557.
17. Gazouli, M., E. Tzelepi, S. V. Sidorenko, and L. S. Tzouvelekis. 1998. Sequence of the gene encoding a plasmid-mediated cefotaxime-hydrolyzing class A β-lactamase (CTX-M-4): involvement of serine 237 in cephalosporin hydrolysis. Antimicrob. Agents Chemother. 42:1259-1262.
18. Goossens, H., M. Ferech, S. Coenen, and P. Stephens. 2007. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin. Infect. Dis. 44:1091-1095.
19. Hawkey, P. M., and A. M. Jones. 2009. The changing epidemiology of resistance. J. Antimicrob. Chemother. 64:i3-i10.
20. Jacoby, G. A., and L. S. Munoz-Price. 2005. The new beta-lactamases. N. Engl. J. Med. 352:380-391.
21. Kalp, M., C. R. Bethel, R. A. Bonomo, and P. R. Carey. 2009. Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are " hypersusceptible"to mechanism-based inhibitors. Biochemistry 48:9912-9920.
22. Kotsakis, S. D., et al. 2010. GES-13, a β-lactamase variant possessing Lys- 104 and Asn-170 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:1331-1333.
23. Leflon-Guibout, V., V. Speldooren, B. Heym, and M. Nicolas-Chanoine. 2000. Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla(TEM) genes. Antimicrob. Agents Chemother. 44: 2709-2714.
24. Lenfant, F., et al. 1993. Site-directed mutagenesis of beta-lactamase TEM-1. Investigating the potential role of specific residues on the activity of Pseudomonas- specific enzymes. Eur. J. Biochem. 217:939-946. (Pubitemid 23326876)
25. Livermore, D. M., et al. 2007. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59:165-174.
26. MacLean, R. C., G. Bell, and P. B. Rainey. 2004. The evolution of a pleiotropic fitness tradeoff in Pseudomonas fluorescens. Proc. Natl. Acad. Sci. U. S. A. 101:8072-8077.
27. Manageiro, V., E. Ferreira, L. Albuquerque, R. Bonnet, and M. Canica. 2010. Biochemical study of a new inhibitor-resistant β-lactamase, SHV-84, produced by a clinical Escherichia coli strain. Antimicrob. Agents Chemother. 54:2271-2272.
28. Martínez, J. L., F. Baquero, and D. I. Andersson. 2007. Predicting antibiotic resistance. Nat. Rev. Microbiol. 5:958-965.
29. Martínez, J. L., et al. 1987. Resistance to beta-lactam/ clavulanate. Lancet ii:1473.
30. Mendonca, N., et al. 2008. The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. Antimicrob. Agents Chemother. 52:1806-1811.
31. Meyer, E., F. Schwab, B. Schroeren-Boersch, and P. Gastmeier. 2010. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit. Care 14:R113.
32. Naas, T., and P. Nordmann. 1999. OXA-type beta-lactamases. Curr. Pharm. Des. 5:865-879.
33. Naseer, U., et al. 2009. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 117:526-536.
34. Neuwirth, C., et al. 2001. TEM-89 β-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. Antimicrob. Agents Chemother. 45:3591-3594.
35. CTX-M harbouring plasmids in Shigella spp. circulating in Southern Vietnam. PLoS Negl. Trop. Dis. 4:e702.
36. Novais, A., et al. 2008. Mutational events in cefotaximase extended-spectrum β-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance. Antimicrob. Agents Chemother. 52:2377-2382.
37. Novais, A., et al. 2010. Evolutionary trajectories of beta-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance. PLoS Pathog. 6:e1000735.
38. Oteo, J., et al. 2010. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J. Antimicrob. Chemother. 65:2459-2463.
39. Oteo, J., M. Pérez-Vazquez, and J. Campos. 2010. Extended-spectrum [beta]- lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr. Opin. Infect. Dis. 23:320-326.
40. Pakyz, A. L., M. Oinonen, and R. E. Polk. 2009. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem- resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:1983-1986.
41. Papp-Wallace, K. M., et al. 2010. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 β-lactamase. Antimicrob. Agents Chemother. 54:2867-2877.
42. Pérez-Llarena, F. J., et al. 2008. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases. J. Antimicrob. Chemother. 61:792-797.
43. Pitout, J. D. 2010. Infections with extended-spectrum beta-lactamaseproducing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70:313-333.
44. Pitout, J. D., and K. B. Laupland. 2008. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166.
45. Pitout, J. D., P. Le, D. L. Church, D. B. Gregson, and K. B. Laupland. 2008. Antimicrobial susceptibility of well-characterized multiresistant CTX-Mproducing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int. J. Antimicrob. Agents 32:333-338.
46. Poirel, L., G. F. Weldhagen, C. De Champs, and P. Nordmann. 2002. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended- spectrum beta-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49:561-565.
47. Pournaras, S., et al. 2009. Clonal spread of KPC-2 carbapenemase- producing Klebsiella pneumoniae strains in Greece. J. Antimicrob. Chemother. 64:348-352.
48. Prinarakis, E. E., V. Miriagou, E. Tzelepi, M. Gazouli, and L. S. Tzouvelekis. 1997. Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob. Agents Chemother. 41:838-840.
49. Qureshi, Z. A., et al. 2011. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int. J. Antimicrob. Agents 37:26-32.
50. Rodríguez-Baño, J., et al. 2008. Community infections caused by extendedspectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 168: 1897-1902.
51. Rodríguez-Baño, J., et al. 2006. Bacteremia due to extended-spectrum betalactamase- producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43:1407-1414.
52. Rodríguez-Baño, J., et al. 2010. Community-onset bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis. 50:40-48.
53. Rodriguez-Villalobos, H., et al. 2011. Trends in production of extendedspectrum beta-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. J. Antimicrob. Chemother. 66:37-47.
54. Sirot, D., et al. 1998. Inhibitor-resistant OXY-2-derived β-lactamase produced by Klebsiella oxytoca. Antimicrob. Agents Chemother. 42:2184-2187.
55. Stapleton, P. D., K. P. Shannon, and G. L. French. 1999. Construction and characterization of mutants of the TEM-1 β-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors. Antimicrob. Agents Chemother. 43: 1881-1887.
56. Tumbarello, M., et al. 2008. Bloodstream infections caused by extendedspectrum- β-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents Chemother. 52:3244-3252.
57. Tumbarello, M., et al. 2010. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-β-lactamase production and inadequate initial antibiotic therapy. Antimicrob. Agents Chemother. 54:4085-4091.
58. Wachino, J., K. Yamane, S. Suzuki, K. Kimura, and Y. Arakawa. 2010. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob. Agents Chemother. 54:3061-3064.
59. Wang, X. D., J. C. Cai, H. W. Zhou, R. Zhang, and G. X. Chen. 2009. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. J. Med. Microbiol. 58:1196-1202.
60. Woodford, N., et al. 2009. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob. Agents Chemother. 53: 4472-4482.
61. Yong, D., et al. 2009. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046-5054.